Maintenance after first-line treatment for advanced soft tissue sarcoma.

Area of Science:

• Oncology
• Medical Therapeutics
• Clinical Trial Analysis

Background:

• Doxorubicin-based chemotherapy is standard for advanced soft tissue sarcoma (STS) but has limited efficacy.
• Salvage treatments for STS often show reduced effectiveness.
• Investigating maintenance therapy for non-progressive STS is crucial due to treatment limitations.

Purpose of the Study:

• To review randomized trials on maintenance therapy in soft tissue sarcoma (STS).
• To identify effective maintenance strategies for improving progression-free survival (PFS) and overall survival (OS).
• To inform the design of future clinical trials for STS maintenance therapy.

Main Methods:

• Systematic review of eight randomized controlled trials (RCTs) on STS maintenance therapy.
• Analysis of continuation maintenance therapy trials.
• Examination of switch maintenance therapy trials.

Main Results:

• Two trials showed improved PFS with continuation maintenance: trabectedin (leiomyosarcoma) and anlotinib (all subtypes).
• One switch maintenance trial with regorafenib improved PFS in nonadipocytic STS.
• Doxorubicin/trabectedin improved OS in leiomyosarcoma; olaratumab results were not confirmed in Phase III.

Conclusions:

• Maintenance therapy, including trabectedin and anlotinib, offers significant PFS benefits in specific advanced STS populations.
• Further research is needed for novel combinations like doxorubicin/pembrolizumab, requiring biomarker identification.
• This review provides a foundation for designing optimized future STS maintenance trials.